Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus ( RSV ) infection
In Vitro
Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor. MCE has not independently confirmed the accuracy of these methods. They are for reference only.